Wu and Gao contributed equally to this work. Mechanistically, TPT1-AS1 was proven to be primarily distributed in EOC cell nuclei and positively modulated TPT1 promoter activity and transcription. Moreover, the oncogenic effects of TPT1-AS1 could be reversed by TPT1 depletion, and the PI3K/AKT signaling pathway downstream of TPT1 was also altered. These results suggested that TPT1-AS1 induced EOC tumor growth and metastasis through TPT1
and serious problems in EOC cases [4] [5] [6] ; therefore, exploring the underlying molecular mechanism of EOC progression and metastasis may help to improve the diagnosis of EOC and the development of novel therapeutic targets.
Long noncoding RNA (lncRNA) are a class of noncoding RNA more than 200 nucleotides long with no protein-coding potential. 7 Through regulating gene expression, lncRNA have crucial roles in multiple biological processes, such as development, differentiation and carcinogenesis. 7 Antisense transcription is from the opposite strand of a protein-coding gene or a sense strand-derived RNA.
Emerging studies show that antisense lncRNA (lncRNA-AS) can function as positive or negative regulators of coding genes to further modulate cancer progression via miRNA decoys or competing endogenous RNA (ceRNA) and other mechanisms. 8, 9 Studies have confirmed that lncRNA tumor protein translationally controlled 1 (TPT1) antisense RNA 1 (TPT1-AS1) functions as a protective lncRNA in glioblastoma. 10 In contrast, TPT1-AS1 has been demonstrated to promote cell growth and metastasis by acting as a ceRNA for miR-324-5p in cervical cancers. 11 However, the roles and mechanisms of TPT1-AS1 in EOC tumorigenesis and progression remain to be elucidated. In this study, the expression of TPT1-AS1
in EOC tissue and cells and the association between TPT1-AS1 and EOC clinicopathological features were investigated. In addition, a series of gain-and loss-of-function experiments were performed to explore the potential roles of TPT1-AS1 in EOC proliferation and metastasis as well as the correlation among TPT1-AS1, TPT1 and the downstream signaling pathway. Our study sheds new light on the understanding of EOC progression and the development of novel drug targets for EOC therapy. 
| MATERIAL S AND ME THODS

| Patients and tissue samples
| Cell culture
The human EOC cell lines ES-2 and SKOV3 and normal human ovarian surface epithelium HOSEpiC cells obtained from our own laboratory were cultured and passaged according to the manufacturer's instructions. All the cell lines were cultured in RPMI-1640 medium (HyClone) containing 10% FBS (Gibco), 100 units/mL of penicillin and 100 mg/mL streptomycin at 37°C in a humidified 5% CO 2 incubator.
| Transfection of lentiviral vectors and siRNA into epithelial ovarian cancer cells
For the ectopic expression of lncRNA TPT1-AS1, ES-2 and SKOV3 cells were transfected with an eGFP lentiviral vector encoding TPT1-AS1 and a negative control vector (LV-TPT1-AS1 and LV-vector, respectively, GeneChem, Shanghai, China) by using polybrene 
| Cell viability assay
Cell proliferation assays were performed using a Cell Counting Kit-8 
| Colony formation assay
For colony formation assays, cells were plated in 6-well plates at a concentration of 150 cells/well and incubated for approximately 2 weeks. Then, colonies of cells were observed, fixed with 100% methanol, and stained with hematoxylin. 
| Cell adhesion assay
| Cell migration and invasion assays
| FISH
FISH probes for TPT1-AS1 were purchased from RiboBio, and DAPI was used as a positive nuclear staining control. Briefly, ES-2 and SKOV3 cells were grown on slides, rinsed gently in PBS, fixed in a 4% formaldehyde solution, permeabilized in PBS containing 0.5% Triton X-100 for 5 minutes at 4°C, and then washed in PBS 3 times for 5 minutes each time. Hybridization was carried out with a FISH probe overnight at 37°C in the dark, and the cells were gradually washed by 4× SSC containing 1% Tween-20, 2× SSC and 1× SSC for 5 minutes in the dark and then counterstained by DAPI to visualize the cell nucleus. Coverslips were mounted onto the glass slides with neutral gum, and the slides were observed by confocal laser scanning microscopy (TCS SP5, Leica).
| Dual luciferase reporter assay
Sequences corresponding to the TPT1-AS1 mRNA transcript and containing the wild-type or mutated TPT1 binding sequence were synthesized by RiboBio (100 nM, RiboBio). These sequences were subcloned into the pGL3-basic luciferase reporter vector (Promega, Madison, WI, USA). SKOV3 cells were cotransfected with the pGL3-basic-TPT1-WT or pGL3-basic-TPT1-MUT reporter plasmids together with the TPT1-AS1 mimic or negative control oligoribonucleotides using X-tremeGENE HP DNA Transfection Reagent (Roche). Firefly and Renilla luciferase activities were detected using a dual luciferase reporter system.
| mRNA decay assay
To analyze the endogenous TPT1 mRNA decay rate, and upregulation 
| Quantitative RT-PCR
Total RNA from ES-2 and SKOV3 cells and EOC tissue samples was extracted by Trizol Reagent (Invitrogen, CA, USA), and cDNA synthesis was performed by using a PrimeScript TM RT Master Mix Kit (TaKaRa BIO, Japan) according to the manufacturer's protocol.
The mRNA level of TPT1-AS1 was detected by using a Super Real PreMix Plus (SYBR Green) Kit (Tiangen Biotech, Beijing, China) and an Applied Biosystems
Step One PlusTM Real-Time PCR System.
The TPT1-AS1 and TPT1 mRNA relative expression levels were calculated using the 2 −ΔΔC t method, and β-actin was used as the positive control. The primers used for real-time PCR were as follows: 
| Western blot analysis
| Statistical analysis
All experiments were repeated at least 3 times in duplicate. Data are presented as the mean ± SD. Differences between the treated and control groups were analyzed using Student's t-test, and the associations between various demographic parameters were evaluated by Fisher's exact test. The level of significance was set at P < 0.05. All statistical analyses were performed with SPSS 24.0 (IBM, NY, USA). 
| TPT1-AS1 promoted the proliferation of epithelial ovarian cancer cells in vitro and in vivo
To investigate the functional role of TPT1-AS1 in cell proliferation and tumor growth, in vitro CCK-8 and colony formation assays and in vivo nude mouse subcutaneous xenograft assays were performed. As the results show, the overexpression of TPT1-AS1 significantly promoted cell proliferation and growth in ES-2 and SKOV3 cells, while the knockdown of TPT1-AS1 expression remarkably inhibited cell survival (P < 0.05; Figure 2A,B) . Moreover, compared with the control groups, the overexpression of TPT1-AS1 dramatically increased the tumor volume and weight of the subcutaneous xenografts in the nude mice (P < 0.05; Figure 2C ), as well as the Ki-67 expression in the xenograft tissues measured by IHC staining (P < 0.001; Figure 2D ).
| TPT1-AS1 promoted epithelial ovarian cancer cell invasion and metastasis in vitro and in vivo
Cell adhesion assay showed that overexpression of TPT1-AS1 significantly attenuated cell adhesion ability, while downregulation of TPT1-AS1 remarkably increased cell adhesion in ES-2 and SKOV3 cells (P < 0.05) ( Figure 3A) . Transwell migration and invasion assays revealed that the overexpression of TPT1-AS1 significantly increased the number of penetrating ES-2 and SKOV3 cells, while the depletion of TPT1-AS1 dramatically inhibited both the cell migratory and invasive capabilities (P < 0.001; Figure 3B ).
F I G U R E 2 Overexpression of TPT1-AS1 significantly promoted epithelial ovarian cancer (EOC) cell proliferation in vitro and in vivo.
A, B, Cell Counting Kit-8 (A) and colony formation assays (B) using the TPT1-AS1-overexpressing or knockdown ES-2 and SKOV3 cells. C, The tumor growth curve and weights of the TPT1-AS1-overexpressing SKOV3 subcutaneous ovarian xenografts. D, Representative immunohistochemical (IHC) staining for Ki-67 in subcutaneous xenograft tumor tissues. Scale bar, 50 μm. Data represent mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001
In addition, the metastasis and dissemination of the xenografts were significantly promoted by TPT1-AS1 expression, as detected with a NightOWL LB 983 In Vivo Imaging System ( Figure 3C ).
The nodular lesions were confirmed to be of EOC tissue origin by pathology experts via H&E staining after dissection (data not shown), and overexpressing TPT1-AS1 could significantly Figure 3D) . Moreover, the numbers and weights of the metastatic nodules (diameter >2 mm)
were also remarkably increased by TPT1-AS1 overexpression (P < 0.05; Figure 3E ). Because of the positive association between TPT1-AS1 and TPT1 expression, the mechanism by which TPT1-AS1 regulates TPT1 was further explored. According to the USCS genome browser bioinformatics analysis, TPT1-AS1 transcripts were located close to the genomic location of TPT1, and 43 nucleotides of TPT1-AS1 were found to be reverse complementary to the TPT1 promoter ( Figure 4F ). In addition, the results of the dual luciferase reporter assay showed that rather than TPT1-MUT, TPT1-AS1
remarkably modulated the TPT1-WT promoter activity in SKOV3 cells (P < 0.05; Figure 4G ). Moreover, the results of the mRNA degradation analysis showed that the upregulation/downregulation of TPT1-AS1 expression did not alter the TPT1 mRNA degradation ratio in SKOV3 cells compared with the control groups ( Figure 4H ).
These results indicated that TPT1-AS1 promoted TPT1 expression by inducing the transcriptional activity of the TPT1 promoter but did not inhibit TPT1 mRNA degradation.
| TPT1-AS1 promoted epithelial ovarian cancer tumorigenesis and metastasis through TPT1 regulation
To further elucidate the mechanisms of TPT1-AS1 in the EOC 
| D ISCUSS I ON
Emerging studies have validated that numerous lncRNA are aberrantly expressed in EOC and play crucial roles in tumorigenesis and progression. 15, 16 For instance, the expression of the lncRNA human ovarian cancer-specific transcript 2 (HOST2) was found to be upregulated in EOC tissue, promoting cell proliferation and metastasis by sponging miRNA let-7b. 17 In addition, highly expressed homeobox (HOX) transcript antisense intergenic RNA (HOTAIR) was found to be closely related to poor EOC prognosis and the promotion of EOC migration and invasion through matrix metalloproteinases (MMP) and epithelial-mesenchymal transition (EMT) in vitro and in vivo. 18 In our previous study, β-hCG was verified to promote the malignant transformation of human ovarian epithelial cells, and significantly facilitate EOC cell migration and invasion through the ERK/MMP2 signaling pathway. 12, 14, 19 In addition, to investigate the underlying mechanisms of β-hCG on EOC dissemination, 1708 lncRNA and 2758 mRNA were found to be differentially expressed in β-hCG dysregulated cell lines by a gene chip (GEO accession number GSE122147, Figure S2A ). During these dysregulated lncRNA, TPT1-AS1 was found to be one of the most upregulated genes, and the functional roles and downstream signaling pathways of TPT1-AS1 were mainly related to cell adhesion and junction ( Figure S2B ).
Therefore, we focused on exploring the function role of TPT1-AS1
in EOC progression.
In the present research, TPT1-AS1 expression was confirmed to be significantly elevated in metastatic EOC tissues and cells, and Interestingly, TPT1-AS1 has been validated to exercise various roles in different tumors. In our study, TPT1-AS1 was proved to promote EOC tumor growth and metastasis through TPT1 and the downstream PI3K/AKT signaling pathway. In cervical cancers, TPT1-AS1 was verified to facilitate cell proliferation, migration and invasion via sponge for miR-324-5p. 11 However, in glioblastoma, TPT1-AS1 was demonstrated to be a protective lncRNA, and to be highly expressed in a low risk group, through binding with inhibitory targets, including AGO2, CPSF7, ELAVL1 and FUS, predicted by CLIP-seq data. 10 The reason lncRNA plays opposite functions in different tumor cells may be due to the different targets it is binding to. [35] [36] [37] [38] Because siRNA mainly exert their gene-silencing effects in cytoplasm, 39, 40 the RNA interference in nuclei does not seem as effective as in cytoplasm. However, in some studies, siRNA were utilized to silence lncRNA and mRNA expression in the nuclei, and the downstream genes and effects were efficaciously regulated. [41] [42] [43] [44] In our study, the TPT1-AS1 depletion EOC cell lines were constructed by siRNA transfection, and were further utilized for in vitro function experiments. As the results showed, the knockdown efficiency of TPT1-AS1 was approximately 30%-40%, and the downregulation of TPT1-AS1 dramatically attenuated EOC cell proliferation, migration and invasion ability, and promoted cell adhesion ability, which are significantly opposite to the oncogenic effects of TPT1-AS1 overexpression. Therefore, despite the low depletion efficiency of siRNA, the tumor inhibitory function was observed; thus, siRNA might work against nuclei TP1-AS1. Efforts have been made to modify antisense oligonucleotide (ASO) drugs to target nuclear lncRNA via RNase H-dependent degradation. [45] [46] [47] Studies have proven that the systemic administration of MALAT-1 ASO inhibitors slows breast tumor growth, which is accompanied by a significant reduction in metastasis. 48 Thus, ASO targeting TPT1-AS1 are worthy of exploration as a potential therapy for inhibiting EOC malignant progression in the future.
Collectively, our study revealed that the lncRNA TPT1-AS1 facilitated EOC tumor growth and metastasis, and inhibited cell adhesion by inducing TPT1 expression and the phosphorylation of molecules of the PI3K and AKT signaling pathway in vitro and in vivo. Our findings suggest that TPT1-AS1 may function as a tumor oncogene in EOC and may be a potential target for inhibiting EOC progression.
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